ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody developed for the treatment of RA (rheumatoid arthritis) and is a novel approach to help tackle this debilitating disease. IL-6 has been identified as having a fundamental role in the inflammation process in RA.
For indication information see RoACTEMRA.
ACTEMRA is currently approved in Japan, US, the European Union (as RoACTEMRA), Switzerland, India, Moldova, Peru, Kuwait, Brazil and Liechtenstein and pending approvals in other countries around the world.
Looking for more detailed information?
For regulatory reasons we are not able to provide further details on our products on this website, but more information may be available on our local website.
Please choose your country of residence to access available information in your language.